Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Borte

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|June 26, 2009
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of lifeGunda Herberth, Joachim Heinrich, Stefan Röder, et al.
Immunotherapy|April 21, 2022
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry studyMichael Borte, Stefan Raffac, Martin Hrubiško, et al.
International Journal of Hygiene and Environmental Health|July 23, 2003
Redecoration of apartments promotes obstructive bronchitis in atopy risk infants--results of the LARS StudyUlrike Diez, Martina Rehwagen, Ulrike Rolle-Kampczyk, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 30, 2010
[Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]Wilhelm Kirch, Ralf Gold, Manfred Hensel, et al.
Journal of Clinical Immunology|September 15, 2012
Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registryMartin Stangel, Ulrich Baumann, Michael Borte, et al.
Journal of Clinical Immunology|June 16, 2011
Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyMichael Borte, Malgorzata Pac, Margit Serban, et al.
The American Journal of Clinical Nutrition|February 8, 2007
Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of ageStefanie Sausenthaler, Sibylle Koletzko, Beate Schaaf, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
Environmental Research|April 24, 2025
Prenatal exposure to mixtures of phthalates and bisphenol A and eczema risk: findings in atopic and non-atopic children from the LiNA birth cohortSergio Gómez-Olarte, Stefan Röder, Ulrike Rolle-Kampczyk, et al.
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|June 26, 2009
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of lifeGunda Herberth, Joachim Heinrich, Stefan Röder, et al.
Immunotherapy|April 21, 2022
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry studyMichael Borte, Stefan Raffac, Martin Hrubiško, et al.
International Journal of Hygiene and Environmental Health|July 23, 2003
Redecoration of apartments promotes obstructive bronchitis in atopy risk infants--results of the LARS StudyUlrike Diez, Martina Rehwagen, Ulrike Rolle-Kampczyk, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 30, 2010
[Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]Wilhelm Kirch, Ralf Gold, Manfred Hensel, et al.
Journal of Clinical Immunology|September 15, 2012
Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registryMartin Stangel, Ulrich Baumann, Michael Borte, et al.
Journal of Clinical Immunology|June 16, 2011
Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyMichael Borte, Malgorzata Pac, Margit Serban, et al.
The American Journal of Clinical Nutrition|February 8, 2007
Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of ageStefanie Sausenthaler, Sibylle Koletzko, Beate Schaaf, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2016
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin Stangel, Ralf Gold, David Pittrow, et al.
Environmental Research|April 24, 2025
Prenatal exposure to mixtures of phthalates and bisphenol A and eczema risk: findings in atopic and non-atopic children from the LiNA birth cohortSergio Gómez-Olarte, Stefan Röder, Ulrike Rolle-Kampczyk, et al.
European Journal of Haematology|May 4, 2017
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyMarcel Reiser, Michael Borte, Dörte Huscher, et al.
Pageof 13